The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
This strategic decision will unlock significant value for our scientific and industrial products business
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Subscribe To Our Newsletter & Stay Updated
